Is Point-of-Care Hepatitis C Virus Testing Too Expensive?
RNA testing carries substantial cost burden for hospitals, study finds
Clinical Scorecard: Is Point-of-Care Hepatitis C Virus Testing Too Expensive?
At a Glance
| Category | Detail |
|---|
| Condition | Hepatitis C Virus (HCV) |
| Key Mechanisms | Point-of-care RNA testing vs. traditional two-step testing |
| Target Population | Safety-net populations in emergency departments |
| Care Setting | Emergency departments and outpatient clinics |
Key Highlights
- Point-of-care RNA testing could increase hospital laboratory costs by up to 260%.
- Emergency department testing increased 682% from 2017 to 2024.
- HCV antigen testing is a cost-effective alternative, adding only $11,494 in annual costs.
Guideline-Based Recommendations
Diagnosis
- Consider point-of-care RNA testing for immediate treatment initiation.
Management
- Evaluate cost implications of point-of-care testing versus traditional methods.
Monitoring & Follow-up
- Track antibody positivity rates in different care settings.
Risks
- Increased laboratory costs may impact other testing services.
Patient & Prescribing Data
Patients diagnosed with HCV in emergency departments.
Immediate treatment initiation is possible with rapid RNA tests.
Clinical Best Practices
- Implement targeted deployment strategies for HCV testing.
- Consider HCV antigen testing as a cost-effective alternative.
References
